The histologic spectrum of epithelial neoplasms induced by sorafenib

Journal of the American Academy of Dermatology

Volumn 61, Issue 3, 2009, Pages 522-527

  Kwon, Eun Ji ^a   Kish, L Stephen ^a   Jaworsky, Christine ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIQUID NITROGEN; SORAFENIB; UREA;

ACTINIC KERATOSIS; AGED; ALOPECIA; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG INDUCED CANCER; FATIGUE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; HYPERTENSION; INVASIVE CARCINOMA; KERATOACANTHOMA; KIDNEY CARCINOMA; MALE; MYALGIA; PAPULE; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BIOPSY; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; EPITHELIUM; HUMANS; KIDNEY NEOPLASMS; MALE; PYRIDINES; SKIN NEOPLASMS;

EID: 68849111836     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.10.043     Document Type: Article

References (42)

1. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
2. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
3. Kong H.H., Cowen E.W., Azad N.S., Dahut W., Gutierrez M., and Turner M.L. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 56 (2007) 171-172
4. Hong D.S., Reddy S.B., Prieto V.G., Wright J.J., Tannir N.M., Cohen P.R., et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144 (2008) 779-782
5. Strumberg D., Clark J.W., Awada A., Moore M.J., Richly H., Hendlisz A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 (2007) 426-437
6. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
7. Dasanu C.A., Dutcher J., and Alexandrescu D.T. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 100 (2007) 328-330
8. Agero A.L., Dusza S.W., Benvenuto-Andrade C., Busam K.J., Myskowski P., and Halpern A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55 (2006) 657-670
9. Marquez C.B., Smithberger E.E., Bair S.M., Wenham R.M., Fenske N.A., Glass L.F., and Cherpelis B.S. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control 16 (2009) 66-69
10. Dubauskas Z., Kunishige J., Prieto V.G., Jonasch E., Hwu P., and Tannir N.M. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7 (2009) 20-23
11. Schwartz R.A. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 30 (2004) 326-333
12. Ghadially F.N., Barton B.W., and Kerridge D.F. The etiology of keratoacanthoma. Cancer 16 (1963) 603-611
13. Maydan E., Nootheti P.K., and Goldman M.P. Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid. J Drugs Dermatol 5 (2006) 804-806
14. D'Addario S., and Carrington P.R. Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses. Acta Derm Venereol 86 (2006) 366-367
15. Lain E.L., and Markus R.F. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol 3 (2004) 680-682
16. O'Donnell B.P., Dawson N.A., Weiss R.B., Myers C.E., and James W.D. Suramin-induced skin reactions. Arch Dermatol 128 (1992) 75-79
17. Kobayashi K., Pezen D.S., Vogelzang N.J., Medenica M., Janisch L., Ratain M., et al. Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol 132 (1996) 96-98
18. Sina B., and Adrian R.M. Multiple keratoacanthomas possibly induced by psoralens and ultraviolet A photochemotherapy. J Am Acad Dermatol 9 (1983) 686-688
19. Craddock K.J., Rao J., Lauzon G.J., and Tron V.A. Multiple keratoacanthomas arising post-UVB therapy. J Cutan Med Surg 8 (2004) 239-243
20. Cox S. Rapid development of keratoacanthomas after a body peel. Dermatol Surg 29 (2003) 201-203
21. Poleksic S., and Yeung K.Y. Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease?. Cancer 41 (1978) 12-16
22. Lacouture M.E., Desai A., Soltani K., Petronic-Rosic V., Laumann A.E., Ratain M.J., et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 31 (2006) 783-785
23. Timpson P., Wilson A.S., Lehrbach G.M., Sutherland R.L., Musgrove E.A., and Daly R.J. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67 (2007) 9304-9314
24. Timpson P., Lynch D.K., Schramek D., Walker F., and Daly R.J. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 65 (2005) 3273-3280
25. Kalish L.H., Kwong R.A., Cole I.E., Gallagher R.M., Sutherland R.L., and Musgrove E.A. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 10 (2004) 7764-7774
26. Erjala K., Sundvall M., Junttila T.T., Zhang N., Savisalo M., Mali P., et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12 (2006) 4103-4111
27. Burnworth B., Arendt S., Muffler S., Steinkraus V., Bröcker E.B., Birek C., et al. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur J Cell Biol 86 (2007) 763-780
28. Wimmer E., Kraehn-Senftleben G., and Issing W.J. HER3 expression in cutaneous tumors. Anticancer Res 28 (2008) 973-979
29. Schlauder S.M., Calder K.B., Moody P., and Morgan M.B. HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 29 (2007) 559-563
30. Groves R.W., Allen M.H., and MacDonald D.M. Abnormal expression of epidermal growth factor receptor in cutaneous epithelial tumors. J Cutan Pathol 19 (1992) 66-72
31. Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103 (2006) 7817-7822
32. Brueckl W.M., Schoeberl A., Wirtz R.M., Murray S., Hahn E.G., and Wiest G.H. Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol 3 (2008) 314-316
33. Bianco R., Rosa R., Damiano V., Daniele G., Gelardi T., Garofalo S., et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14 (2008) 5069-5080
34. Detmar M., Velasco P., Richard L., Claffey K.P., Streit M., Riccardi L., et al. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol 156 (2000) 159-167
35. Tong M., Lloyd B., Pei P., and Mallery S.R. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 105 (2008) 1202-1210
36. Pierceall W.E., Goldberg L.H., Tainsky M., Mukhopadhyay T., and Ananthaswamy H. N ras gene mutation and amplification in human non-melanoma skin cancers. Mol Carcinog 4 (1991) 196-202
37. van der Schroeff J.G., Evers L.M., Boot A.J., and Bos J.L. Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 94 (1990) 423-425
38. Arbiser J.L. Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. J Invest Dermatol 129 (2009) 538-540
39. Spencer J.M., Kahn S.M., Jiang W., DeLeo V.A., and Weinstein I.B. Activated ras genes occur in human actinic keratoses, premalignant precursors to SCCs. Arch Dermatol 131 (1995) 796-800
40. Hipp M.M., Hilf N., Walter S., Werth D., Brauer K.M., Radsak M.P., et al. Sorafenib but not sunitinib affects the function of dendritic cells and the induction of primary immune responses. Blood 111 (2008) 5610-5620
41. Zhao W., Gu Y.H., Song R., Qu B.Q., and Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22 (2008) 1226-1233
42. Gollob J.A., Wilhelm S., Carter C., and Kelley S.L. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33 (2006) 392-406